Join to View Full Profile
6431 Fannin St# MsbHouston, TX 77030
Phone+1 713-500-6868
Fax+1 713-500-6882
Dr. Kala is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jaya Kala is a nephrologist in Houston, TX and is affiliated with Memorial Hermann - Texas Medical Center. She received her medical degree from Lady Hardinge Medical College and has been in practice 14 years.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Nephrology, 2013 - 2015
Cleveland Clinic Foundation/Akron GeneralResidency, Internal Medicine, 2010 - 2013
Lady Hardinge Medical CollegeClass of 2003
Certifications & Licensure
TX State Medical License 2015 - 2025
OH State Medical License 2010 - 2013
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
Clinical Trials
- Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury Start of enrollment: 2019 Sep 26
Publications & Presentations
PubMed
- 1 citationsDiagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology.Sandra M Herrmann, Ala Abudayyeh, Shruti Gupta, Prakash Gudsoorkar, Nattawat Klomjit
Kidney International. 2025-01-01 - 1 citationsAcute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies.Jaya Kala, Teresa Joseph, Marta Pirovano, Roberta Fenoglio, Laura Cosmai
Kidney360. 2024-11-01 - Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology.Abhijat Kitchlu, Verônica T Costa E Silva, Shuchi Anand, Jaya Kala, Ala Abudayyeh
Clinical Journal of the American Society of Nephrology. 2024-08-01
Press Mentions
New Economic Analysis of Voraxaze® (Glucarpidase) in Patients with Delayed MethotrexateMarch 15th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
